News
The sell-off erased an estimated $70 billion in market value, slashing Novo Nordisk's valuation to around $287 billion, down ...
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...
Join Ramzan Karmali as he takes a closer look at today's Trending stock Tickers - Adidas, the sportswear giant - Novo Nordisk ...
Novo Nordisk ( NVO) continued its downward spiral and fell 3.8% in premarket trade, a day after the Danish drugmaker slashed ...
17h
Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition
Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...
Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 sales.
The pharmaceutical giant said multiple entities were still marketing and selling unbranded versions of its drug despite U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback